StockNews.AI
SLNO
StockNews.AI
15 hrs

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

1. Pomerantz LLP investigates potential securities fraud by Soleno Therapeutics. 2. Claims relate to allegations against officers and directors of the company. 3. Scorpion Capital reported Vykat XR as overpriced and unsafe for children. 4. Soleno's stock dropped 7.41% after the August report, closing at $71.63. 5. Investors are encouraged to join the class action for potential remedies.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The investigation for securities fraud and negative reports severely damage investor confidence, reminiscent of past cases where stock values plummeted due to such allegations, indicating potential long-term sell-offs.

How important is it?

The article highlights serious legal concerns and immediate threats to SLNO’s price, likely to deter investors and harm market perception.

Why Short Term?

Immediate investor reaction to fraud allegations typically results in significant stock price declines, which can remain volatile until the situation stabilizes, as seen in previous fraud allegations within the biotech sector.

Related Companies

VRTXADPTKPTI
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 15, 2025, Scorpion Capital (“Scorpion”) published a report that described Soleno’s only product, Vykat XR, as overpriced and potentially unsafe for children. Following publication of the Scorpion report, Soleno’s stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News